Aurinia Pharmaceuticals Inc.

Effective March 23, 2026, the Company appointed Kevin Tang as Chief Executive Officer, Ryan Cole as Chief Operating Officer, and Michael Hearne as Chief Financial Officer. Effective March 20, 2026, Peter Greenleaf, President, Chief Executive Officer and Director, Matthew Donley, Chief Operating Officer, Gregory Keenan, M.D., Chief Medical Officer, and Joseph Miller, Chief Financial Officer ceased to serve as officers of Aurinia, and Mr. Greenleaf resigned from the Board of Directors of Aurinia effective March 21, 2026. In connection with their terminations of employment, each former officer entered into a separation agreement with the Company. Per the terms of the agreements, each former officer was provided with a severance package substantially as set out in his employment agreement. Mr. Greenleaf, Mr. Donley, Dr. Keenan and Mr. Miller are continuing to serve as consultants through June 20, 2026 in order to facilitate the management transition.